Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Fecha de publicación: 01/01/2022

Autores de IIS La Fe

Marina Berenguer Haym

Autor

Participantes ajenos a IIS La Fe

Martin P.
Awan A.A.
Bruchfeld A.
Fabrizi F.
Goldberg D.S.
Jia J.
Kamar N.
Mohamed R.
Pessôa M.G.
Pol S.
Sise M.E.
Balk E.M.
Gordon C.E.
Adam G.
Cheung M.
Earley A.
Jadoul M.

Grupos

Hepatología, Cirugia Hepatobiliopancreática y Trasplantes

Abstract

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection. © 2022 International Society of Nephrology

Datos de la publicación

ISSN/ISSNe:: 0085-2538, 1523-1755
Tipo:: Article
Páginas:: 1228-1237
DOI:: 10.1016/j.kint.2022.07.012
PubMed:: 36411019
Enlace a otro recurso:: www.scopus.com
Factor de Impacto:: 4,063 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Martin P.:: Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, United States
Awan A.A.:: Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States
Berenguer M.C.:: Department of Gastroenterology, Hepatology Unit & Instituto de Investigación La Fe, Hospital Universitari i Politècnic La Fe, Valencia, Spain

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Valencia, Spain

School of Medicine, University of Valencia, Valencia, Spain
Bruchfeld A.:: Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden

Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden
Fabrizi F.:: Division of Nephrology, Maggiore Hospital and Foundation IRCCC Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
Goldberg D.S.:: Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, United States
Jia J.:: Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Beijing Key Laboratory of Transitional Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Diseases, Beijing, China
Kamar N.:: Departments of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France

INFINITY- Inserm U1291-CNRS U5051, Toulouse, France

Université Paul Sabatier, Toulouse, France
Mohamed R.:: Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia
Pessôa M.G.:: Division of Clinical Gastroenterology and Hepatology, Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil
Pol S.:: Hepatology Department, Hopital Cochin, Université Paris Descartes, Paris, France
Sise M.E.:: Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States
Balk E.M.:: Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI, United States
Gordon C.E.:: Tufts Medical Center, Division of Nephrology, Boston, MA, United States
Adam G.:: Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI, United States
Cheung M.:: Kidney Disease: Improving Global Outcomes (KDIGO), Brussels, Belgium
Earley A.:: Kidney Disease: Improving Global Outcomes (KDIGO), Brussels, Belgium
Jadoul M.:: Department of Nephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium

Keywords

Glomerular Filtration Rate; Hepacivirus; Hepatitis C; Humans; Kidney; Renal Insufficiency, Chronic; alanine aminotransferase; antivirus agent; aspartate aminotransferase; avelumab; creatinine; cryoglobulin; dasabuvir; entecavir; grazoprevir; hepatitis B core antibody; hepatitis B surface antibody; hepatitis B surface antigen; interferon; lamivudine; ledipasvir plus sofosbuvir; leukocyte antigen; mammalian target of rapamycin; mycophenolate mofetil; ombitasvir; paritaprevir; ribavirin; rilpivirine; ritonavir; rituximab; simeprevir; sofosbuvir; tacrolimus; virus DNA; Article; blood donor; blood transfusion; cardiovascular disease; chronic hepatitis B; chronic kidney failure; creatinine blood level; cryoglobulinemia; disease severity; disease transmission; end stage renal disease; estimated glomerular filtration rate; genotype; glomerulonephritis; glomerulopathy; glomerulus filtration rate; graft survival; hematuria; hemodialysis; hepatitis B; hepatitis C; Hepatitis C virus; Hepatitis C v

Cita

Cita Bibliográfica